Morgan Stanley
TCRT icon

Morgan Stanley’s Alaunos Therapeutics TCRT Stock Holding History

Morgan Stanley’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.87K Sell
653
-994
-60% -$2.97K ﹤0.01% 7345
2025
Q4 		$5.32K Sell
1,647
-37
-2% -$120 ﹤0.01% 7051
2025
Q3 		$4.06K Sell
1,684
-114
-6% -$325 ﹤0.01% 7149
2025
Q2 		$8.72K Buy
1,798
+901
+100% +$2.71K ﹤0.01% 6896
2025
Q1 		$1.32K Sell
897
-149
-14% -$244 ﹤0.01% 7247
2024
Q4 		$1.99K Sell
1,046
-291
-22% -$647 ﹤0.01% 7200
2024
Q3 		$4.3K Sell
1,337
-157
-11% -$564 ﹤0.01% 6952
2024
Q2 		$10.4K Sell
1,494
-216
-13% -$2.58K ﹤0.01% 6668
2024
Q1 		$30.9K Sell
1,710
-1,553
-48% -$31K ﹤0.01% 6369
2023
Q4 		$34.6K Buy
3,263
+1,080
+49% +$13K ﹤0.01% 6477
2023
Q3 		$43.2K Sell
2,183
-1,865
-46% -$80.3K ﹤0.01% 6228
2023
Q2 		$310K Sell
4,048
-375
-8% -$30.3K ﹤0.01% 5453
2023
Q1 		$418K Sell
4,423
-5,043
-53% -$480K ﹤0.01% 5355
2022
Q4 		$922K Buy
9,466
+4,493
+90% +$651K ﹤0.01% 4915
2022
Q3 		$1.28M Sell
4,973
-874
-15% -$254K ﹤0.01% 4733
2022
Q2 		$1.09M Sell
5,847
-570
-9% -$54.5K ﹤0.01% 4961
2022
Q1 		$628K Buy
6,417
+422
+7% +$54.2K ﹤0.01% 5275
2021
Q4 		$981K Sell
5,995
-308
-5% -$67.7K ﹤0.01% 5079
2021
Q3 		$1.72M Sell
6,303
-673
-10% -$206K ﹤0.01% 4683
2021
Q2 		$2.76M Buy
6,976
+815
+13% +$380K ﹤0.01% 4368
2021
Q1 		$3.33M Sell
6,161
-2,145
-26% -$1.34M ﹤0.01% 3830
2020
Q4 		$3.14M Buy
8,306
+2,399
+41% +$954K ﹤0.01% 3765
2020
Q3 		$2.23M Sell
5,907
-252
-4% -$111K ﹤0.01% 3559
2020
Q2 		$3.03M Sell
6,159
-2,772
-31% -$1.24M ﹤0.01% 3180
2020
Q1 		$3.28M Buy
8,931
+1,060
+13% +$549K ﹤0.01% 2874
2019
Q4 		$5.57M Sell
7,871
-3,183
-29% -$2.19M ﹤0.01% 3085
2019
Q3 		$7.1M Buy
11,054
+1,820
+20% +$1.44M ﹤0.01% 2488
2019
Q2 		$8.07M Buy
9,234
+1,079
+13% +$742K ﹤0.01% 2392
2019
Q1 		$4.71M Sell
8,155
-1,354
-14% -$566K ﹤0.01% 2773
2018
Q4 		$2.67M Buy
9,509
+1,673
+21% +$661K ﹤0.01% 3529
2018
Q3 		$3.76M Sell
7,836
-614
-7% -$263K ﹤0.01% 3481
2018
Q2 		$3.83M Sell
8,450
-630
-7% -$399K ﹤0.01% 3455
2018
Q1 		$5.34M Sell
9,080
-942
-9% -$587K ﹤0.01% 2964
2017
Q4 		$6.22M Buy
10,022
+1,038
+12% +$746K ﹤0.01% 2856
2017
Q3 		$8.27M Sell
8,984
-533
-6% -$473K ﹤0.01% 2475
2017
Q2 		$8.88M Sell
9,517
-3,744
-28% -$3.67M ﹤0.01% 2283
2017
Q1 		$12.6M Buy
13,261
+2,165
+20% +$2.02M ﹤0.01% 1982
2016
Q4 		$8.9M Buy
11,096
+1,814
+20% +$1.63M ﹤0.01% 2378
2016
Q3 		$7.84M Sell
9,282
-71
-0.8% -$57.1K ﹤0.01% 2230
2016
Q2 		$7.7M Buy
9,353
+46
+0.5% +$50.1K ﹤0.01% 2204
2016
Q1 		$10.4M Sell
9,307
-1,481
-14% -$1.52M ﹤0.01% 1832
2015
Q4 		$13.4M Buy
10,788
+524
+5% +$867K ﹤0.01% 1740
2015
Q3 		$13.9M Buy
10,264
+170
+2% +$281K 0.01% 1677
2015
Q2 		$18.2M Buy
10,094
+990
+11% +$1.54M 0.01% 1580
2015
Q1 		$14.7M Buy
9,104
+281
+3% +$416K 0.01% 1705
2014
Q4 		$6.71M Buy
8,823
+338
+4% +$179K ﹤0.01% 2438
2014
Q3 		$3.36M Buy
8,485
+562
+7% +$271K ﹤0.01% 3000
2014
Q2 		$4.79M Buy
7,923
+193
+2% +$107K ﹤0.01% 2705
2014
Q1 		$5.31M Buy
7,730
+804
+12% +$539K ﹤0.01% 2527
2013
Q4 		$4.51M Buy
6,926
+2,387
+53% +$1.42M ﹤0.01% 2668
2013
Q3 		$2.68M Buy
4,539
+917
+25% +$413K ﹤0.01% 2991
2013
Q2 		$1.15M Buy
+3,622
New +$1.01M ﹤0.01% 3616

Other funds holding TCRT

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Morgan Stanley's TCRT Position: Q1 2026 in Review

Morgan Stanley reduced its Alaunos Therapeutics (TCRT) stake by 60% in Q1 2026, selling an estimated $2.97K and leaving 653 shares worth $1.87K. The position accounts for ﹤0.01% of the portfolio, ranked #7345.

Morgan Stanley first reported a position in TCRT in Q2 2013 and has held it in 52 quarters since. The position peaked at $18.2M in Q2 2015. 29 funds tracked by Wall St. Rank hold TCRT as of Q1 2026.

  • Morgan Stanley held 653 shares of Alaunos Therapeutics worth $1.87K as of Q1 2026.
  • Morgan Stanley sold 994 Alaunos Therapeutics shares in Q1 2026, an estimated $2.97K.
  • Alaunos Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #7345 holding.
  • Morgan Stanley first reported a position in Alaunos Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • Morgan Stanley's Alaunos Therapeutics position peaked at $18.2M in Q2 2015.
  • 29 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.